{"name":"F. Stephen Hodi, MD","slug":"f-stephen-hodi-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxPOGc4UTZZd2oxbnVtOTJtaGo4dXBnZ0o2SHlNYk1ReHBKZ1dNUWp3Nkl3c1dwQjNMTVdPa3dpVEM5THBqTktmWkxkZ0lvN2JPa0U1TU9OOUoyRkxrUGpRM2tTWGhKZDBBclJZbkx6cGtlRkxTdXg3Q1F2VFlLQjhiRWMzd0oxMm5VdjRnMV9udmNVWUpUTUk3NUczZlAtUk1pTnFkc1NITVNjdzFCR2ZsakNFRzRudHZ5NXNtUVlpSlo3UERGeWRwMkFTNjgxNUFNWlQzUHUwOW5lMTBBeG5pY3BRWWFJalgwRjdxLTdla1J0VEVfWW5UNlRydC1YcXUwcS1wU3J0SVI4aEZFMEpxMGxWeDJ3YjhCRWxDRlJpS09ZVUJBNjlTdU4xQWdCMEJSOHppUzh4ZWVacU5iWFdNWG95RlN5a0gtZHhTLVFIWlpiSThncFBmYmRScUxCMFZ3QV9rcw?oc=5","date":"2024-04-18","type":"pipeline","source":"prnewswire.com","summary":"Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Associated with Immune Checkpoint Inhibitors (ICIs) in the Treatment of Cancer - pr","headline":"Comprehensive Review Highlights Potential Benefits of Leukine® in Management of Gastrointestinal (GI) Adverse Events Ass","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOVlJ3SVMxcEUxNElraGJubTRpaFppbUNtSkdfdndBWEU3aWNIbEctN2JQOXpWT3VCT1V3RzlrbG54MkI1ZE5xWERQZDhNTFB4eC1USGxmc1Y3LWY5Si1QN0dHQmZiUW9XemI3WmwwWDVrbURhNm85cWtBeWJHd2JJX3NZdFVDVEg0THNpVkl4ZzNNN2RjRFBmU1RmWlZQeXlmQjFMaWM1b2xQdXFIdWNKTE81Z0RqYnBwdWc?oc=5","date":"2022-03-21","type":"regulatory","source":"Healio","summary":"FDA approves Opdualag for unresectable or metastatic melanoma - Healio","headline":"FDA approves Opdualag for unresectable or metastatic melanoma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxNZVpaczl2SnFRQ2tOT3Ewc3R4LXpJeXBjc1Q2a1R1ZTlXX0JGaHFZTVJlZ2JQMGI4ZHdTaUo4bTl0RWVlTnd4Z0FFZ0hHU2RadVd4RW4xV0d1Ml8xbGRjM0FlcEI1UklWSGs1cDB4MXZrVF9yV2xMaGg0SW50SDlvVjBoODVSRzB4V01VOWpxWXU5SkxvZGxBejJxS2VESWduSkJ3OHlxUTJwc2U2NTlTUGlzQjExcFhGMnFrRlBueloyWE1wVWJSTy1kczJBaUIwSFJEQkpHN2cxZ3ZSVmxmZWYwb3RncmdQaVBJcDN3Ty0wZWdoU2p3UEZRR3NoNE01Y0dHeVZRenJpb2JCZURseUFKVWkzTi03cmQtR0liRVZBaXdpUzNVSTZOblNiYldpanFzN1g0c1RFc3R5TV9CYmZ0akZ1Y01wQmxuQ05Na09KUHJ1MzNubFZjUFhOa3c?oc=5","date":"2022-03-18","type":"regulatory","source":"news.bms.com","summary":"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma - ne","headline":"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlima","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBOQ0g3dE0yT0E1WERhLVp6NFRXTkFzZzVwMVVoOHUwQVFqcm14Q3h1bUlEaDlrSThjSEktMmJPQmdVb3ZpN1NYbUc2aW5YdFA2eWZYSkRBWXBROTZLamc?oc=5","date":"2019-10-23","type":"pipeline","source":"Samoa Observer","summary":"Compass Therapeutics Appoints Leading Immuno-Oncology - Samoa Observer","headline":"Compass Therapeutics Appoints Leading Immuno-Oncology","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9HSUJidVQyQXJ2SnlvWkZQV3A1S0J2eC1wSXRQN2J0cXp2bXZZSk5lamw3dmo3aVdRbGp2SWFYWHVLOTZLa29pcVM0VXViSU5vMy0ycFljYWpPUHNZSkI0OC1tV2s2NG95VloyaW1pbXdhSzht?oc=5","date":"2013-02-07","type":"pipeline","source":"Wiley","summary":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab - Wiley","headline":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5sclVvNU9waGRkUVQ0OGYxSVRheW0xek15eFpDekZOS1RNai1ReUhoZzBaVE0wR0Q3cG1NYU1DUFNBeTBxNDJ5RGYxNHBJVmQ3NklGLUZNcVh2a3k3QmhTSg?oc=5","date":"2012-06-02","type":"pipeline","source":"NEJM","summary":"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer - NEJM","headline":"Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}